Combining THEMIS2-targeted therapies with immune checkpoint inhibitors could potentially transform the immunologically “cold” TME of GBM into a “hot” one, increasing tumor immunogenicity and improving patient outcomes [2,30,31,32]. This evidence concerns the gene THEMIS2 and neoplasm.